Vitamin D status in primary hyperparathyroidism: a Southern European perspective.

What Was Tested

This observational study looks at Vitamin D, K2, Magnesium and Zinc in the context of hyperparathyroidism.

Vitamin D deficiency (VDD) is common in patients with primary hyperparathyroidism (pHPT), and this could affect the clinical expression of the disease.

However, few North American or North European studies have addressed this issue, showing vitamin D repletion in only about one-third of the patients.

Who Took Part

The abstract describes 206 patients taking part.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Vitamin D status was evaluated both in an observational study in a series of 206 consecutive patients with pHPT at diagnosis and in a case-control analysis with 113 age- and sex-matched healthy blood donors.

How the Study Was Run

Vitamin D status was assessed by measuring plasma 25-hydroxy-vitamin D (25OHD) levels and was defined as VDD or severe VDD if 25OHD was <20 ng/ml (<50 nm) and <10 ng/ml (<25 nm), respectively.

What Was Measured

Vitamin D deficiency (VDD) is common in patients with primary hyperparathyroidism (pHPT), and this could affect the clinical expression of the disease.

The subject headings attached to it are Bone Density, Calcifediol, Case-Control Studies, Europe, Hyperparathyroidism, Primary, Prevalence and Vitamin D Deficiency.

What This Means in Plain Language

This is an observational study of Vitamin D, K2, Magnesium and Zinc in 206 patients in people with hyperparathyroidism.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Clinical endocrinology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Hyperparathyroidism research.